Bank Julius Baer & Co. Ltd, Zurich Neurocrine Biosciences Inc Transaction History

Bank Julius Baer & Co. Ltd, Zurich

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 May 16, 2024	BUY	$106.07 - $132.76 $114,979 - $143,911	1,084 New	1,084 $142,000
Q4 2023 Feb 02, 2024	SELL	$106.07 - $132.76 $1,378 - $1,725	-13 Reduced 1.19%	1,084 $143,000
Q3 2023 Nov 13, 2023	BUY	$94.02 - $117.1 $103,139 - $128,458	1,097 New	1,097 $123,000
Q4 2022 Jan 24, 2023	BUY	$106.72 - $127.06 $84,735 - $100,885	794 Added 47.26%	2,474 $295,000
Q3 2022 Nov 04, 2022	BUY	$92.03 - $107.81 $154,610 - $181,120	1,680 New	1,680 $178,000
Q2 2022 Jul 22, 2022	SELL	$75.79 - $100.07 $11,368 - $15,010	-150 Closed	0 $0
Q1 2022 May 09, 2022	BUY	$72.45 - $94.81 $10,867 - $14,221	150 New	150 $14,000

635

93.5M

632K

621K

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $14.1B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

Get notified when there are updates to the investment portfolio of Bank Julius Baer & Co. Ltd, Zurich, based on Form 13F filings with the SEC.

Stay updated on Bank Julius Baer & Co. Ltd, Zurich with notifications on news.